The future of cytotoxic cancer therapies lies in improving selectivity and reducing side effects. Advances in nanotechnology allow for targeted delivery of cytotoxic drugs, enhancing their efficacy and minimizing collateral damage. Additionally, combining cytotoxic agents with immunotherapies and precision medicine approaches holds promise for more effective and personalized cancer treatment strategies.
